Can cataract be prevented?

Eye (Basingstoke)

Volumn 13, Issue 3, 1999, Pages 454-456

  Harding, John J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Aldose reductase inhibitors; Anticataract therapy; Aspirin; Cataract; Ibuprofen; Paracetamol

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; IBUPROFEN; PARACETAMOL;

ARTICLE; CATARACT; HUMAN; RISK FACTOR;

EID: 0032814744     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.1999.121     Document Type: Article

References (30)

1. Minassian DC, Mehra V. 3.8 million blinded by cataract every year: projections from the first epidemiological study of incidence of cataract blindness in India. Br J Ophthalmol 1990;74:341-3.
2. Pokharel GP, Regmi G, Shrestha SK, Negrel AD, Ellwein LB. Prevalence of blindness and cataract surgery in Nepal. Br J Ophthalmol 1998;82:600-5.
3. Eckstein M, Vijayalakshmi P, Killedar M, Gilbert C, Foster A. Use of intraocular lenses in children with traumatic cataract in south India. Br J OphthalmoI1998;82:911-5.
4. Tielsch JM. Appropriate technology for cataract surgery. Lancet 1998;352:754-5.
5. Pokharel GP, Selvaraj S, Ellwein LB. Visual functioning and quality of life outcomes among cataract operated and unoperated blind populations in Nepal. Br J Ophthalmol 1998;82:606-10.
6. Axelsson U. Miotic-induced cataract. Ciba Found Symp 1973;19:249-63.
7. Pirie A. Chairman’s concluding remarks. Ciba Found Symp 1973;19:311-3.
8. Harding JJ, van Heyningen R. Case-control study of cataract in Oxfordshire. Dev Ophthalmol 1987;15:99-103.
9. Minassian DC, Mehra V, Verrey JD. Dehydrational crises: a major risk factor in blinding cataract. Br J Ophthalmol 1989;73:100-5.
10. Crabbe MJC, Goode D. Aldose reductase: a window to the treatment of diabetic complications? Prog Ret Eye Res 1998;17:313-83.
11. Bron AJ, Brown NAP, Harding JJ, Ganea E. The lens and cataract in diabetes. Int Ophthalmol Clin 1998;38:37-67.
12. Harding JJ. Cataract: biochemistry, epidemiology and pharmacology. London: Chapman and Hall, 1991.
13. Cotlier E, Sharma YR. Aspirin and senile cataracts in rheumatoid arthritis. Lancet 1981;1:338-9.
14. Lin PP, Barry RC, Smith DL, Smith JB. In vivo acetylation identified at lysine 70 of human lens aA-crystallin. Protein Sci 1988;7: 1451-7.
15. Crompton M, Rixon KC, Harding JJ. Aspirin prevents carbamylation of lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract. Exp Eye Res 1985;40:213-222.
16. Bucala R, Manabe S, Urban RC, Cerami A. Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies. Exp Eye Res 1985;41:353-63.
17. Rao GN, Cother E. Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro. Biochem Biophys Res Commun 1988;151:991-6.
18. Huby R, Harding JJ. Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione. Exp Eye Res 1988;47:53-9.
19. Ajiboye R. Harding JJ. The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione. Exp Eye Res 1989;49:31-41.
20. Roberts KA, Harding JJ. Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose. Exp Eye Res 1990;50:157-64.
21. Raza K, Harding JJ. Non-enzymic modification of lens proteins by glucose and fructose, effects of ibuprofen. Exp Eye Res 1991;52:205-12.
22. van Heyningen R, Harding JJ. Do aspirin-like drugs protect against cataract? Lancet 1986;1:1111-3.
23. Harding JJ, van Heyningen R. Drugs including alcohol that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide. Br J Ophthalmol 1988;72:809-14.
24. Harding JJ, Egerton M, Harding RS. Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol 1989;67:518-24.
25. Eckerskorn U, Hockwin O, Muller-Breitenkamp R, Chen TT, Knowles W, et al. Evaluation of cataract-related risk factors using detailed classification systems and multivariate statistical methods. Dev Ophthalmol 1987;15:82-91.
26. Mohan M, Sperduto RD, Surander KA, Milton RC, Mathur RL, et al. India-US case-control study of age-related cataracts. Arch Ophthalmol 1989;107:670-6.
27. Gupta PP, Pandey DN, Pandey DJ, Sharma AL, Srivastava RK. Aspirin in experimental cataractogenesis. Indian J Med Res 1984;80:703-7.
28. Swamy MS, Abraham EC. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest Ophthalmol Vis Sci 1989;30:1120-6.
29. Blakytny R, Harding JJ. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 1992;54:509-18.
30. Evans JR, Rauf A, Sayer AA, Wormald RPL, Cooper C. Agerelated nuclear lens opacities are associated with reduced growth before one year of age. Invest Ophthalmol Vis Sci 1998;39:1740-4.